14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $23.53 $28.69 Friday, 3rd May 2024 INSM stock ended at $25.55. This is 0.429% less than the trading day before Thursday, 2nd May 2024. During the day the stock fluctuated 4.06% from a day low at $25.40 to a day high of $26.43.
90 days $23.53 $29.91
52 weeks $18.09 $32.00

Historical Insmed prices

Date Open High Low Close Volume
Jan 17, 2024 $28.24 $28.99 $28.07 $28.81 1 691 462
Jan 16, 2024 $28.32 $28.82 $27.89 $28.38 2 094 309
Jan 12, 2024 $28.63 $29.06 $28.19 $28.46 1 056 211
Jan 11, 2024 $27.70 $28.60 $27.33 $28.39 1 969 423
Jan 10, 2024 $28.90 $29.33 $28.20 $28.34 1 443 153
Jan 09, 2024 $29.61 $29.61 $28.44 $29.11 2 818 519
Jan 08, 2024 $28.94 $29.95 $28.53 $29.93 2 437 100
Jan 05, 2024 $28.87 $29.48 $28.60 $29.35 1 047 771
Jan 04, 2024 $28.69 $29.68 $28.68 $29.13 1 689 482
Jan 03, 2024 $29.35 $29.74 $28.57 $28.68 2 057 205
Jan 02, 2024 $30.80 $31.14 $29.36 $29.94 1 819 118
Dec 29, 2023 $31.74 $31.79 $30.99 $30.99 743 981
Dec 28, 2023 $31.67 $32.00 $31.39 $31.74 930 685
Dec 27, 2023 $31.07 $31.64 $30.95 $31.64 898 462
Dec 26, 2023 $30.34 $31.19 $30.31 $31.02 1 057 936
Dec 22, 2023 $29.76 $30.89 $29.50 $30.04 1 171 780
Dec 21, 2023 $28.04 $29.43 $27.93 $29.42 1 608 624
Dec 20, 2023 $28.97 $29.22 $27.65 $27.71 1 384 293
Dec 19, 2023 $28.82 $29.27 $28.78 $29.13 1 141 014
Dec 18, 2023 $28.46 $28.79 $27.94 $28.71 1 202 386
Dec 15, 2023 $29.00 $29.21 $28.13 $28.42 3 651 446
Dec 14, 2023 $29.03 $29.23 $28.19 $28.88 1 849 589
Dec 13, 2023 $28.00 $28.83 $27.58 $28.71 1 445 264
Dec 12, 2023 $27.24 $28.05 $26.77 $27.99 1 612 475
Dec 11, 2023 $27.93 $28.10 $26.93 $27.26 1 230 165
Click to get the best stock tips daily for free!

About Insmed

Insmed Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutr... INSM Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT